Cargando…

Efficacy of immune checkpoint inhibitors for in-transit melanoma

BACKGROUND: The efficacy of immune checkpoint inhibitors (ICI) in metastatic melanoma is well established. However, there are limited data regarding their efficacy in in-transit melanoma (ITM). This study assessed the efficacy of ICI in patients with ITM. METHODS: A retrospective review of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nan Tie, Emilia, Lai-Kwon, Julia, Rtshiladze, Michael Alexander, Na, Lumine, Bozzi, James, Read, Tavis, Atkinson, Victoria, Au-Yeung, George, Long, Georgina V, McArthur, Grant A, Sandhu, Shahneen, Saw, Robyn, Walpole, Euan, Menzies, Alexander, Smithers, Mark, Gyorki, David E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223285/ https://www.ncbi.nlm.nih.gov/pubmed/32376722 http://dx.doi.org/10.1136/jitc-2019-000440

Ejemplares similares

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series
por: Banks, Patricia D., et al.
Publicado: (2019)

OR32-06 Opportunistic Assessment of Pituitary Gland with Routine MRI and PET/CT Can Guide in Earlier and Increased Identification of Hypophysitis in Patients Treated with Combination Checkpoint Inhibitors
por: Galligan, Anna, et al.
Publicado: (2020)

Systemic therapies for unresectable locoregional melanoma: a significant area of need
por: Nan Tie, Emilia, et al.
Publicado: (2019)

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report
por: Hultin, Sebastian, et al.
Publicado: (2020)

Results of a phase II, open‐label, non‐comparative study of intralesional PV‐10 followed by radiotherapy for the treatment of in‐transit or metastatic melanoma
por: Foote, Matthew, et al.
Publicado: (2017)

Case series: Immune checkpoint inhibitor-induced transverse myelitis
por: Chatterton, Sophie, et al.
Publicado: (2023)

Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
por: Johnson, Douglas B., et al.
Publicado: (2023)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study
por: Read, Tavis, et al.
Publicado: (2017)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”
por: Tsang, Venessa H M, et al.
Publicado: (2020)

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
por: Hong, David S., et al.
Publicado: (2022)

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study
por: Read, Tavis A., et al.
Publicado: (2018)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

SUN-127 Diagnostic Challenges Associated with the Rising Incidence of Endocrine Toxicity in the Era of Combination Immunotherapy
por: Galligan, Anna, et al.
Publicado: (2020)

Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor
por: Pham, J. P., et al.
Publicado: (2021)

i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol
por: Hyatt, Amelia, et al.
Publicado: (2020)

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2020)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Novel radionuclide therapy combinations in prostate cancer
por: Inderjeeth, Andrisha–Jade, et al.
Publicado: (2023)

What does an aetiological diagnosis actually mean?
por: Smithers‐Sheedy, Hayley, et al.
Publicado: (2022)

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
por: Lelliott, Emily J., et al.
Publicado: (2021)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Wu, Linda, et al.
Publicado: (2021)

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
por: Patrinely, J. Randall, et al.
Publicado: (2021)

Bridging education and training in ageing and disability: the European Care Certificate (ECC)
por: Churchill, James, et al.
Publicado: (2009)

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
por: Pirozyan, Mehdi R., et al.
Publicado: (2020)

Current management of patients with melanoma who are found to be sentinel node‐positive
por: Nijhuis, Amanda A. G., et al.
Publicado: (2019)

Locoregional melanoma: identifying optimal care in a rapidly changing landscape
por: Gyorki, David E, et al.
Publicado: (2019)

An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?
por: Downs, Jennifer S, et al.
Publicado: (2019)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_auhf77crsjqpggm643mlbetglb